Fly News Breaks for January 3, 2020
Jan 3, 2020 | 08:51 EDT
Canaccord analyst Kyle Rose noted NuVasive announced its CFO was stepping down and while acknowledging senior management changes bring risk of disruption, he does not see any material risk to the company from this change. He said NuVasive remains one of the more attractive names in medtech with robust new product flow, a stable and improving US spine market, and a clear margin expansion opportunity. Rose reiterated his Buy rating and $80 price target on NuVasive shares.
News For NUVA From the Last 2 Days
There are no results for your query NUVA